Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and ...

The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.

Johnson & Johnson gained Inlexzo, formerly known as TAR-200, when it acquired privately held Taris Biomedical in 2019. The deal gave J&J a treatment it says could change way the “non-muscle invasive” ...

RC and BST showed similar patient-reported and clinical outcomes after one year, with RC initially impacting physical function more negatively. RC was linked to better emotional and cognitive function ...